Drugs in ATC Class B02

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Subclasses in ATC: B02 - ANTIHEMORRHAGICS

B02A - ANTIFIBRINOLYTICS

B02B - VITAMIN K AND OTHER HEMOSTATICS

B02 Market Analysis and Financial Projection

The market dynamics and patent landscape for ATC Class B02 (Antihemorrhagics) reflect a rapidly evolving sector driven by innovation in biologics, gene therapies, and expanding applications in bleeding disorder treatments. Below is a structured analysis:

---

Market Overview

The global antihemorrhagic drugs market is part of the broader $46.2B anticoagulant/antithrombotic sector (projected 2024–2028 CAGR: 7.9%)[3]. Specifically, bleeding disorders treatments (hemophilia A/B, von Willebrand disease) are forecast to grow from $13.28B (2021) to $19.22B by 2027 (CAGR: 6.36%)[13]. Key drivers include:

• Rising prevalence of coagulation disorders and aging populations.
• Advancements in gene therapies and recombinant clotting factors.
• Increased adoption of non-invasive diagnostics and earlier disease detection[10][11].

---

Key Drug Categories under B02

1. B02A (Antifibrinolytics): Inhibit fibrinolysis (e.g., aminocaproic acid).
2. B02B (Vitamin K and Hemostatics):
   • Vitamin K analogs (e.g., phytonadione).
   • Blood coagulation factors (e.g., recombinant Factor VIII/IX).
   • Local hemostatics (e.g., fibrinogen-impregnated gauze)[1][7].

---

Innovations and Patent Trends

• Gene Therapies:

  • Hemgenix (etranacogene dezaparvovec): Approved for hemophilia B, achieving 63% reduction in annualized bleeding rates (ABR) vs. prophylactic FIX[10].
  • Beqvez (fidanacogene elaparvovec): Phase III trials showed 71% ABR reduction[11].
  • These therapies fall under B02BD (Blood Coagulation Factors) and leverage AAV vectors for sustained factor expression[10][11].

• Biologics Dominance: Biologics like coagulation factors (e.g., Lovenox) account for >75% of B02 patents[6]. Unlike small molecules, biologics exhibit longer patent lifecycles and higher R&D costs[16].

• Patent Activity:

  • 3M, SABIC, and Evonik Industries lead in PET-based medical innovations, but niche players like CSL Behring and Pfizer dominate B02B through gene therapy patents[2][10][11].
  • Over 1,400 Medical PET patents (2010–2024) highlight material advancements (e.g., biocompatible polymers)[2].

---

Regional Market Dynamics

• North America: Largest market share (45%) due to high healthcare spending and early adoption of gene therapies[3][10].
• Europe: Strong growth in recyclable/biodegradable PET materials for drug delivery[2].
• Asia-Pacific: Fastest-growing region (9.1% CAGR) driven by rising hemophilia diagnoses in India and China[3][12].

---

Commercialization Challenges

• High Costs: Gene therapies like Hemgenix cost ~$3.5M per dose, limiting accessibility[10][11].
• Regulatory Hurdles: Stringent safety requirements for biologics delay approvals (e.g., ANNEXA-4 trial for andexanet alfa took 6 years)[14].
• Patent Cliffs: Expiry of key biologics (e.g., Lovenox) opens opportunities for biosimilars but pressures revenue[3][6].

---

Future Outlook

• Gene Editing: CRISPR-based therapies (e.g., targeting F8/F9 mutations) could revolutionize hemophilia A/B treatment[15].
• Sustainability Focus: Bio-based PET polymers (e.g., SABIC’s recyclable PET) aim to reduce environmental impact[2].
• Market Expansion: Partnerships (e.g., Pfizer and Sangamo) aim to address underserved populations in Latin America and Africa[11][12].

---

"The shift from replacement therapies to gene-based solutions marks a paradigm shift in hemophilia care, offering potential cures rather than temporary fixes." – Industry Analyst[10].

---

Key Takeaways

1. B02 Antihemorrhagics are transitioning from traditional factor replacements to gene therapies.
2. Patent landscapes prioritize biologics, with gene therapies dominating recent approvals.
3. Cost and regulatory barriers remain critical challenges, particularly in emerging markets.
4. Sustainability and collaborative R&D are key to long-term market growth.

FAQs

1. What distinguishes B02A from B02B drugs?
   B02A targets fibrinolysis inhibition, while B02B includes vitamin K and coagulation factors for deficiency-related bleeding.

2. How do gene therapies impact hemophilia treatment costs?
   While upfront costs are high, gene therapies reduce long-term expenses by minimizing factor replacement needs.

3. Which companies lead in B02B patent filings?
   CSL Behring (Hemgenix) and Pfizer (Beqvez) are pioneers, alongside Sanofi (Lovenox) for traditional anticoagulants.

4. What role does PET innovation play in antihemorrhagics?
   Advanced PET materials improve drug delivery systems (e.g., heat-resistant polymers for factor VIII storage)[2].

5. Are biosimilars a threat to existing B02B biologics?
   Yes, patent expirations (e.g., 2025–2030) will likely increase biosimilar competition, lowering prices[6][16].

References

1. https://atcddd.fhi.no/atc_ddd_index/?code=B02&showdescription=yes
2. https://www.businesswire.com/news/home/20250110674650/en/Medical-PET-Patent-Landscape-Report-2025-Covering-1408-Patents-Filed-from-2010-to-2024---ResearchAndMarkets.com
3. https://www.bccresearch.com/pressroom/phm/antithrombotic-anticoagulant-drugs-market-forecasted-to-surge-to-$462-billion-by-2028
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC2898493/
5. https://investor.bridgebio.com/static-files/894eecb0-bac5-4fac-97a5-d2feb91f6783
6. https://dspace.mit.edu/bitstream/handle/1721.1/62181/Bernt-2010-Characterizing%20Markets%20for%20Biopharmaceutical%20Innovations%20Do%20Biologics%20Differ%20from%20Small%20Molecules.pdf?sequence=1&isAllowed=y
7. https://atcddd.fhi.no/atc_ddd_index/?code=B02B
8. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1622556
9. https://www.atccode.com/B02
10. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1715173505610
11. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1728318721334
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5384749/
13. https://www.prnewswire.com/news-releases/global-bleeding-disorders-treatment-market-report-2022-industry-trends-share-size-growth-opportunities-and-forecasts-2021-2027-301726133.html
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC6061403/
15. https://www.biorxiv.org/content/10.1101/2023.02.10.527980v3.full-text
16. https://www.econstor.eu/bitstream/10419/108554/1/821105345.pdf
17. https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID2575651_code916374.pdf?abstractid=2391786&mirid=1